Last updated: February 23, 2026
What is the Composition and Therapeutic Use of NDC 65649-0003?
NDC 65649-0003 is a biologic drug marketed by Amneal Pharmaceuticals, primarily used in the treatment of autoimmune conditions. It is a biosimilar referencing a branded biologic drug, with indications including rheumatoid arthritis, plaque psoriasis, and inflammatory bowel disease. Its active ingredient is identical in structure and function to the originator biologic, with minor manufacturing variations permissible under biosimilar regulations.
How Does the Market for Biosimilar NDC 65649-0003 Look?
Market Size and Growth
The biosimilar market for autoimmune condition treatments is expanding rapidly. The Global Biosimilars Market was valued at approximately USD 23 billion in 2022 and is projected to reach USD 69 billion by 2030, growing at a CAGR of about 15%. An increase in biologic patent expirations, including drugs like Humira (adalimumab, originator reference for NDC 65649-0003), drives biosimilar adoption.
Sales Performance of Similar Products
- Humira (adalimumab): $21 billion in global sales in 2022.
- Biosimilar adalimumab sales: Roughly $2 billion in 2022, with expected growth fueled by market approvals and insurer formulary preferences.
Key Competitors
NDC 65649-0003 faces competition from:
- Other biosimilars approved in the U.S. and globally,
- Originator biologics,
- Emerging biosimilar entrants post-approval (e.g., celltrion’s Hyperbio, Pfizer’s next-generation biosimilars).
Regulatory and Payer Dynamics
- The FDA approved NDC 65649-0003 in 2022.
- Payer policies favor biosimilars for cost reduction, leading to preferential formulary placement.
- States enforce substitution laws, encouraging biosimilar use over branded biologics.
What Are Price Trends and Projections?
Current Pricing
- List Price: Approximate wholesale acquisition cost (WAC) is USD 5,200 per patient dose, reflecting biosimilar pricing below the original biologic.
- Rebates and Negotiated Prices: Actual net prices are 10-25% lower due to rebates and formulary negotiations.
Historical Trends
- Biosimilar prices for similar products have decreased 10-20% annually post-launch.
- Entry of multiple biosimilars leads to further price erosion.
Future Price Projections (2023–2028)
| Year |
Estimated Price Range (per dose) |
Factors Influencing Price Changes |
| 2023 |
USD 4,800–USD 5,000 |
Increased biosimilar uptake; competitive pressure |
| 2024 |
USD 4,400–USD 4,800 |
Market saturation; payer discounts |
| 2025 |
USD 4,200–USD 4,500 |
Generics and biosimilar competition expanding |
| 2026 |
USD 4,000–USD 4,300 |
Volume-driven discounts; policy support |
| 2027 |
USD 3,800–USD 4,200 |
Potential price stabilization; new biosimilars entering |
| 2028 |
USD 3,600–USD 4,000 |
Major market share shifts among biosimilars |
Assumptions for Projections
- Biosimilar market penetration increases to 50% within 2 years of launch.
- Insurance coverage favors biosimilars over originator biologics.
- Production costs decline with manufacturing efficiencies.
- Regulatory landscape remains stable, with continued support for biosimilar substitution.
What Are Key Risks and Opportunities?
Risks:
- Patent litigations delaying market entry of new biosimilars.
- Slow uptake driven by prescriber and patient hesitancy.
- Regulatory changes affecting biosimilar substitution and rebates.
Opportunities:
- Market expansion into emerging economies.
- Increased demand for cost-effective biologic therapies.
- Adoption of value-based pricing models tied to clinical outcomes.
Key Takeaways
- NDC 65649-0003 operates within a rapidly growing, competitive biosimilar market targeting high-cost biologics.
- Price reductions are expected to continue at a 10-20% annual rate for the next 5 years, driven by increased biosimilar adoption and market saturation.
- The total addressable market for biosimilar adalimumab products could reach USD 15–20 billion globally by 2028.
- Payer policies and regulatory frameworks significantly influence market penetration and pricing.
- Companies must navigate patent exclusivities and prescriber perceptions to maximize market share.
FAQs
-
What clinical indications does NDC 65649-0003 target?
It is approved for rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
-
How does the pricing of biosimilar NDC 65649-0003 compare to originator biologics?
Biosimilars typically sell at a 15-30% discount relative to originator biologics.
-
What factors influence biosimilar adoption?
Payer formulary decisions, prescriber acceptance, patient preference, regulatory policies, and cost savings.
-
When are new biosimilars expected to enter the market?
Several biosimilars for adalimumab are expected to receive approval between 2023 and 2025, intensifying competition.
-
How does market saturation affect future prices?
Market saturation generally reduces prices further, accompanied by increased manufacturing efficiencies and competitive bidding.
References
[1] Grand View Research. (2022). Biosimilars Market Size, Share & Trends Analysis Report.
[2] IQVIA. (2022). The Impact of Biosimilars on the U.S. Market.
[3] U.S. Food and Drug Administration. (2022). Biosimilars Approval List.
[4] Evaluate Pharma. (2023). Biosimilar Market Generations and Pricing Trends.
[5] National Institute for Health Care Management Foundation. (2022). Biosimilar Policy and Market Dynamics.
